Imodium consumer lawsuit
This article was originally published in The Tan Sheet
Executive Summary
Proposed class action filed on behalf of retail purchasers of Imodium Advanced asserts claims for unlawful monopoly, unfair trade practices, unjust enrichment against McNeil. Filed in Philadelphia federal court July 2, complaint alleges J&J division unlawfully extended patent protection for loperamide/simethicone combination through improper patent filings, denying consumers access to lower-priced generic alternatives. Complaint filed by members of Prescription Access Litigation project marks PAL's first lawsuit involving an OTC drug. Case is assigned to Judge Berle Schiller, who last month declared McNeil's patent claims invalid (1"The Tan Sheet" July 1, 2002, p. 3). McNeil calls PAL lawsuit "baseless," notes product faces substantial generic competition in anti-diarrheal market...
You may also be interested in...
McNeil Imodium Patent Prosecution Conduct Leads To Perrigo Fee Award
McNeil Consumer & Specialty Pharmaceuticals' "irresponsible" conduct in prosecuting "obvious" patent claims relating to Imodium Advanced justifies awarding Perrigo attorneys' fees in a patent infringement case, a Philadelphia federal judge ruled June 25
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.